ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

被引：0

作者：

Peterson, Peter ^{[1
]}

Soh, Katherine K. ^{[1
]}

Lee, Ye Sol ^{[2
]}

Kim, Wontak ^{[1
]}

Whatcott, Clifford J. ^{[1
]}

Siddiqui-Jain, Adam ^{[3
]}

Bearss, David J. ^{[3
]}

Warner, Steven L. ^{[3
]}

机构：

[1] Tolero Pharmaceut Inc, Discovery Biol, Lehi, UT USA

[2] Tolero Pharmaceut, Discovery Biol, Lehi, UT USA

[3] Tolero Pharmaceut Inc, Lehi, UT USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 12 条

[1] TP-0184 IS AN INHIBITOR OF ALK2 AND A POTENTIAL THERAPEUTIC FOR THE TREATMENT OF ANEMIA OF CHRONIC DISEASE
Peterson, Peter
Kim, Wontak
Haws, Hillary
Whatcott, Clifford
Siddiqui-Jain, Adam
Bearss, David
Warner, Steven
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) : E355 - E355
[2] TP-0184 LOWERS HEPCIDIN LEVELS AND IS A POTENTIAL THERAPEUTIC FOR ANEMIA OF CHRONIC DISEASE
Peterson, P.
Bahr, B.
Soh, K.
Bearss, J.
Kim, W.
Whatcott, C.
Siddiqui-Jain, A.
Bearss, D.
Warner, S.
HAEMATOLOGICA, 2015, 100 : 188 - 188
[3] Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease
Kim, Wontak
Maughan, Kyle S.
Soh, Katherine K.
Bearss, Jeremiah J.
Bahr, Brigham L.
Bearss, David J.
Warner, Steven L.
BLOOD, 2014, 124 (21)
[4] TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency
Peterson, Peter W. K.
Whatcott, Clifford
Siddiqui-Jain, Adam
Weitman, Steven
Kieran, Mark
Bearss, David J.
Warner, Steven L.
BLOOD, 2017, 130
[5] A CONNECT CONSORTIUM PRECLINICAL STUDY IDENTIFIES MEK INHIBITION AND RADIATION AS POTENTIAL COMBINATION PARTNERS FOR THE ALK2 INHIBITOR TP-0184 IN ACVR1-MUTANT DMG
Rogers, Rebecca
Tsoli, Maria
Kumar, Shiva Senthil
Potente, Elisabet Fernandez
Biery, Matt
Grabovska, Yura
Mackay, Alan
Carvalho, Diana
Pereria, Rita
Burford, Anna
Sejdiu, Drenusha
Ruddle, Ruth
Gabel, Florian
Raynaud, Florence
Yadavilli, Sridevi
Mizoguchi, Sean
Subramaniam, Bavani
Kilburn, Lindsey
Hwang, Eugene
Nazarian, Javad
Vitanza, Nicholas
Ziegler, David
Drissi, Rachid
Jones, Chris
NEURO-ONCOLOGY, 2023, 25
[6] A Monoclonal Antibody Targeting ALK2 As a Potential Therapeutic Agent for Anemia of Inflammation
Medeiros, Natalia
Backus, Thomas A.
Mater, Christopher
Fisher, Ffolliott
Lachey, Jenn
Seehra, Jasbir
BLOOD, 2021, 138
[7] The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease
Peterson, Peter
Kim, Wontak
Haws, Hillary
Whatcott, Clifford J.
Siddiqui-Jain, Adam
Bearss, David J.
Warner, Steven L.
BLOOD, 2016, 128 (22)
[8] Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Asshoff, Malte
Petzer, Verena
Warr, Matthew R.
Haschka, David
Tymoszuk, Piotr
Demetz, Egon
Seifert, Markus
Posch, Wilfried
Nairz, Manfred
Maciejewski, Pat
Fowles, Peter
Burns, Christopher J.
Smith, Gregg
Wagner, Kay-Uwe
Weiss, Guenter
Whitney, J. Andrew
Theurl, Igor
BLOOD, 2017, 129 (13) : 1823 - 1830
[9] Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation
Jain, Mukul
Joharapurkar, Amit
Patel, Vishal
Kshirsagar, Samadhan
Sutariya, Brijesh
Patel, Maulik
Patel, Hiren
Patel, Pankaj R.
EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 843 : 113 - 120
[10] The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents
Asshoff, Malte
Warr, Matthew
Haschka, David
Tymoszuk, Piotr
Petzer, Verena
Demetz, Egon
Maciejewski, Pat
Seifert, Markus
Nairz, Manfred
Posch, Wilfried
Fowles, Peter
Weiss, Guenter
Whitney, Andy
Theurl, Igor
BLOOD, 2015, 126 (23)

← 1 2 →